Oric Pharmaceuticals Inc
ORIC10.780USD
-0.080-0.74%
Close 09/12, 16:00（ET）Quotes delayed by 15 min
929.10MMarket Cap
LossP/E TTM
More Details of Oric Pharmaceuticals Inc Company
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Company Info
Ticker SymbolORIC
Company nameOric Pharmaceuticals Inc
IPO dateApr 24, 2020
CEODr. Jacob M. Chacko, M.D.
Number of employees115
Security typeOrdinary Share
Fiscal year-endApr 24
Address240 E. Grand Ave
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94080
Phone16503885600
Websitehttps://oricpharma.com/
Ticker SymbolORIC
IPO dateApr 24, 2020
CEODr. Jacob M. Chacko, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
778.65K
+1.01%
Dr. Richard A. (Rich) Heyman, Ph.D.
Dr. Richard A. (Rich) Heyman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
228.77K
--
Dr. Kevin Brodbeck, Ph.D.
Dr. Kevin Brodbeck, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Dominic G. Piscitelli, CPA
Mr. Dominic G. Piscitelli, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Independent Director
Independent Director
--
--
Dr. Lori A. Kunkel, M.D.
Dr. Lori A. Kunkel, M.D.
Independent Director
Independent Director
--
--
Dr. Angie J. You, Ph.D.
Dr. Angie J. You, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
778.65K
+1.01%
Dr. Richard A. (Rich) Heyman, Ph.D.
Dr. Richard A. (Rich) Heyman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
228.77K
--
Dr. Kevin Brodbeck, Ph.D.
Dr. Kevin Brodbeck, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Dominic G. Piscitelli, CPA
Mr. Dominic G. Piscitelli, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 31
Updated: Sun, Aug 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nextech Invest, Ltd.
7.37%
EcoR1 Capital, LLC
6.93%
VR Adviser, LLC
6.79%
Viking Global Investors LP
6.77%
Pfizer Inc
5.54%
Other
66.60%
Shareholders
Shareholders
Proportion
Nextech Invest, Ltd.
7.37%
EcoR1 Capital, LLC
6.93%
VR Adviser, LLC
6.79%
Viking Global Investors LP
6.77%
Pfizer Inc
5.54%
Other
66.60%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
28.79%
Investment Advisor
26.57%
Venture Capital
22.65%
Hedge Fund
14.71%
Corporation
5.54%
Private Equity
2.02%
Sovereign Wealth Fund
1.98%
Individual Investor
1.43%
Research Firm
1.21%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
288
93.19M
110.15%
+12.20M
2025Q1
294
83.96M
99.59%
+456.78K
2024Q4
284
80.39M
113.18%
-3.73M
2024Q3
272
78.70M
112.04%
-2.29M
2024Q2
265
76.25M
113.03%
-1.57M
2024Q1
276
71.21M
105.62%
-1.02M
2023Q4
259
57.91M
108.09%
+1.21M
2023Q3
260
55.20M
103.62%
-1.09M
2023Q2
255
52.76M
117.11%
+8.95M
2023Q1
257
40.28M
89.44%
-3.51M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nextech Invest, Ltd.
5.29M
6.2%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
3.42M
4.01%
--
--
Mar 31, 2025
VR Adviser, LLC
6.60M
7.74%
+3.41M
+107.28%
Apr 08, 2025
Viking Global Investors LP
6.57M
7.71%
+2.14M
+48.33%
Mar 31, 2025
Pfizer Inc
5.38M
6.31%
--
--
Mar 31, 2025
SR One Capital Management, LP
4.62M
5.42%
+4.62M
--
May 29, 2025
New Enterprise Associates (NEA)
2.20M
2.58%
+629.46K
+40.19%
Mar 31, 2025
Alkeon Capital Management LLC
3.34M
3.92%
+86.63K
+2.66%
Mar 31, 2025
The Column Group LP
3.54M
4.15%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.40M
5.16%
+59.93K
+1.38%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
0.93%
SPDR S&P Biotech ETF
0.11%
iShares Micro-Cap ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
iShares Biotechnology ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.03%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion0.93%
SPDR S&P Biotech ETF
Proportion0.11%
iShares Micro-Cap ETF
Proportion0.1%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.06%
iShares Biotechnology ETF
Proportion0.05%
Fidelity Enhanced Small Cap ETF
Proportion0.05%
Avantis US Small Cap Equity ETF
Proportion0.05%
Vanguard US Momentum Factor ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
